Embolog S®
Product Description
EmboLog® S is intended for embolization of blood vessels, especially for the local application in minimal invasive treatment, such as intra-arterial occlusion in liver tumour therapy. It used as an adjuvant in the intra-arterial treatment of inoperable liver and lung tumours in combination with cytostatic agents, aiming to optimize intra-tumoral drug accumulation.
Embolog S is available as a suspension for injection. It is typically provided in vials containing 450 mg of Degradable Starch Microspheres (DSM) in 7.5 ml of isotonic saline solution. The embolization effect of EmboLog S leads to a short-term vascular occlusion of blood vessels and reduced blood flow. When cytostatic drugs are administered prior to the intended embolization, the effect of Embolog S leads to an increased duration of exposure of the cytostatic drug at the target area.
Launched Markets
Taiwan, Singapore, Thailand, Malaysia, Philippines, Vietnam, Indonesia
The information on this page is provided for general informational purposes only and is not intended to promote, advertise, or recommend the use of any specific pharmaceutical product, medical device, or treatment. It is not a substitute for professional medical advice, diagnosis, or treatment.
Product availability, indications, and regulatory status may vary by country and are subject to local laws and health authority approvals. Prescription products mentioned here are intended for reference purposes only and should not be purchased, used, or administered without consultation with, and prescription by, a qualified healthcare professional.
Please consult your physician, pharmacist, or other qualified healthcare provider for advice regarding any medical condition or before using any product referenced on this website.
